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original work is propObjective: Preexposure prophylaxis (PrEP) is a promising intervention to help end the
HIV epidemic among men who have sex with men (MSM) in the Netherlands. We
aimed to assess the impact of PrEP on HIV prevalence in this population and to
determine the levels of PrEP coverage necessary for HIV elimination.
Design and methods: We developed a mathematical model of HIV transmission in a
population stratified by sexual risk behavior with universal antiretroviral treatment
(ART) and daily PrEP use depending on an individual’s risk behavior. We computed the
effective reproduction number, HIV prevalence, ART and PrEP coverage for increasing
ART and PrEP uptake levels, and examined how these were affected by PrEP effective-
ness and duration of PrEP use.
Results: At current levels of ART coverage of 80%, PrEP effectiveness of 86% and PrEP
duration of 5 years, HIV elimination required 82% PrEP coverage in the highest risk
group (12 000 MSMwith more than 18 partners per year). If ART coverage increased by
9%, the elimination threshold was at 70% PrEP coverage. For shorter PrEP duration and
lower effectiveness elimination prospects were less favorable. For the same number of
PrEP users distributed among two groups with highest risk behavior, prevalence
dropped from the current 8 to 4.6%.
Conclusion: PrEP for HIV prevention amongMSMcould, in principle, eliminateHIV from
this population in theNetherlands. The highest impact of PrEP on prevalencewas predicted
when ART and PrEP coverage increased simultaneously and PrEP was used by the highest
risk individuals. Copyright  2018 The Author(s). Published by Wolters Kluwer Health, Inc.AIDS 2018, 32:2615–2623Keywords: HIV elimination, HIV prevalence, mathematical modeling, men who
have sex with men, preexposure prophylaxis, preexposure prophylaxis coverageIntroduction
As stated by the Joint United Nations Programme on
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in the corresponding groups [2]. However, we are still far
from stopping HIV transmission, especially in MSM who
accounted for 68% of new HIV diagnoses in 2016 [2].
At present preexposure prophylaxis (PrEP) is considered
to be one of the most promising interventions to help end
the HIV epidemic in this population [3,4]. Daily or
intermittent PrEP uptake was shown to be effective in
preventing HIV transmission among MSM in trials [5,6],
cohort [7] and clinical practice studies [8,9]. The body of
modeling work assessing PrEP impact in different settings
has been growing in the last several years. Research has
mostly focused on the cost-effectiveness of PrEP in the
context of the Netherlands [10] and other countries [11–
13]. Modeling studies predicted the pivotal role of PrEP
in reducing HIV incidence in MSM, particularly in the
United Kingdom [14]. However, these studies mainly
investigated short-term impact of PrEP on HIV
transmission by examining reduction in HIV incidence.
The question of the possibility of HIV elimination by
PrEP and the levels of PrEP uptake necessary to achieve it
has not been addressed systematically in the literature.
The current guideline by the Dutch Association of HIV-
treating Physicians recommends PrEP use by MSM at
high risk of HIVacquisition [15]. The high price of this
preventive medication has been the main limitation for a
large-scale implementation of PrEP intervention in the
Netherlands. PrEP coverage among MSM is below 10%
[16]. However, changes in PrEP uptake are expected to
occur as the price of PrEP has recently dropped by 80%
[17]. The knowledge to aid PrEP rollout in the
Netherlands will be provided by a PrEP study known
as the Amsterdam PrEP Project [18] running from June
2015. As part of Amsterdam PrEP Project, real-world
data on the uptake by high-risk MSM of daily and
intermittent PrEP, medication adherence and change in
risk behavior when taking PrEP will be collected by the
Public Health Service Amsterdam until December
2018 [18].
Our aim was to investigate the potential impact of PrEP
on the HIV epidemic among MSM in the Netherlands
using a mathematical transmission model. The model
assumed universal ARTof the population and daily PrEP
use depending on an individual’s risk behavior. We
estimated the reduction in HIV prevalence for increasing
levels of PrEP uptake and determined which levels
of PrEP uptake, effectiveness and duration would be
necessary for HIV elimination.Methods
Model formulation and assumptions
The mathematical model described HIV transmission
among MSM through unprotected sex. The model wasbased on our previous model [19] which we extended to
include PrEP. We stratified the population into four risk
groups by the average number of new sexual partners per
year. The model allowed to vary mixing between the risk
groups. As estimates of the degree of assortative mixing
in the population of MSM in the Netherlands are not
available, we assumed intermediate mixing. Intermediate
mixing implies that half of partnerships are formed
within the same risk group and the remaining half are
formed with individuals from other risk groups,
proportionally to the number of partnerships offered
by those risk groups. Average duration of sexual activity
was 45 years.
The compartments in the model represented individuals
who were susceptible, infected in four disease stages
(primary infection, chronic infection, AIDS stage with
onset of severe symptoms, terminal AIDS stage without
sexual activity) and those treated in four stages. Infection
stages had different infectivities and duration. Infectivity
of individuals on ART was reduced and did not differ
between the stages. The model assumed universal ART
and that treatment uptake was the same in all infection
stages and risk groups. A small percentage of treated
individuals could drop off ART and return to the
respective infected stage.
We considered two scenarios for daily PrEP use. In the
first scenario, PrEP could be taken by the highest risk
individuals only. In real world, PrEP will probably be
more commonly used in the highest risk population but
likely in other risk groups as well. For this reason in our
second scenario, PrEP was taken by individuals in two
groups with highest risk. When PrEP was taken by the
two highest risk groups we kept PrEP uptake rate equal in
both groups. To be able to make a comparison of the two
scenarios we adjusted the rate of PrEP uptake in the
second scenario so that the total number of individuals on
PrEP in the two highest risk groups was the same as the
number of PrEP users in the highest risk group in the first
scenario. The average duration of PrEP use and PrEP
effectiveness could be varied. The effectiveness was
defined as the relative reduction in the rate of HIV
infection due to PrEP use [5]. At 100% effectiveness PrEP
users never got infected. At 0% effectiveness PrEP users
got infected with the same rate as non-PrEP users.
Infectivity of individuals who acquired HIV while taking
PrEP was assumed to be lower than infectivity of MSM
who did not take PrEP. As individuals taking PrEP are
regularly tested for HIV (every 3 months in the AMPrEP
study [18]), in the model infected PrEP users started
treatment during primary infection.
The model was implemented as a system of ordinary
differential equations in the Mathematica software by
Wolfram Research (version 10.0.2). The detailed model
description and equations are given in the Supplementary
Material, http://links.lww.com/QAD/B377.
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We computed the effective reproduction number, Re,
using next generation matrix theory described in detail
elsewhere [20,21]. This quantity served as a measure of
HIV transmission potential in the presence of ART and
PrEP and was used to define the conditions for HIV
elimination. Mathematically, Re is defined as the average
number of secondary infections caused by a typical
infectious individual in a population, where intervention
measures are implemented. Although Re is a mathemati-
cal concept used in modeling studies, it is useful for HIV
prevention and elimination policy planning. Specifically,
Re allows to quantify the effort necessary for eliminating a
disease. In theory, disease elimination occurs if Re is below
1. In what follows, we referred to parameters for which
HIV elimination occurred as parameters for which
Re¼ 1, that is at the threshold of elimination.
Model outputs
We numerically solved the model equations to determine
three steady-state quantities: HIV prevalence, PrEP
coverage per risk group and population level ART
coverage. HIV prevalence was computed as the percent-
age of HIV infected in the population in the steady state.
PrEP coverage was defined per risk group as the
percentage of HIV-negative individuals who were on
PrEP in that group in the steady state. Population level
ART coverage was defined as the percentage of HIV-
infected individuals who were on treatment in the
steady state.
Model parameters
Most parameter values were taken from the existing
literature (Supplementary Table 1, http://links.lww.-
com/QAD/B377). Behavioral parameters were esti-
mated from data. The average number of new partners
per year was determined from sexual behavior data on the
self-reported number of sexual partners in the last 6
months for MSM in the Netherlands by Rutgers World
Population [22], using the method described in detail in
Rozhnova et al. [19]. In this method, we used the actual
number of partners for respondents who reported
inconsistent condom use. The respondents who always
used condoms were assumed to have zero sexual partners.
We used population stratification by risk from Rozhnova
et al. [19] in which three groups with highest risk were
grouped into one. The resulting percentages of MSM in
the four risk groups were 45.1, 35.3, 12.5 and 7.1%. The
average numbers of new partners per year (range) were
0.13 (0–0.45), 1.43 (0.45–3.35), 5.44 (3.35–8.88) and
18.21 (8.88–500), respectively.
Default PrEP parameters were effectiveness of 86% [5,6]
and duration of 5 years [10]. We assumed that infectivity
of individuals on PrEP was half the infectivity of non-
PrEP users and that 95% of individuals who got infected
while taking PrEP started ART within 1 year. These
assumptions were relaxed in the sensitivity analyses of themodel (refer to Fig. 2 in the Supplementary Material,
http://links.lww.com/QAD/B377).
We presented our results in terms of the model parameters
such as annual ART and PrEP uptake percentages (range
0–100%). The former and the latter were defined
respectively as the percentage of infected individuals
starting ART and the percentage of HIV-negative
individuals initiating PrEP within 1 year. For given
annual PrEP and ART uptake percentage we computed
steady-state ARTand PrEP coverage as the model output.
Annual ART uptake percentage and probability of
transmission per partnership were free parameters in the
model. We fixed annual ART uptake at 30% and
probability of transmission per partnership at 0.25 in the
baseline model scenario without PrEP to describe the
current state of the Dutch HIVepidemic among MSM.
HIV prevalence and ART coverage in the model (before
PrEP) were about 8% (estimate for MSM in the
Netherlands [23]) and 80% (estimate by HIV
Monitoring Foundation [2]), respectively. Population
size in the absence of interventions was 210 000
individuals.Results
PrEP use by highest risk individuals was an efficient way
to reduce steady-state HIV prevalence and to drive HIV
to elimination (Fig. 1). Assuming baseline ARTuptake of
30%, steady-state prevalence dropped from 8 to 6.1% if
PrEP uptake was 20% annually, and from 8 to 3.7% for
40% uptake (Fig. 1a). The elimination (zero prevalence
and Re just below 1 in Fig. 1a) was reached at PrEP uptake
of 64% which translated into 82% PrEP coverage
(Fig. 1b). As in the steady state the highest risk group
was about 7% of the population, this coverage implied
that 5.7% of all MSM had to be taking PrEP to achieve
elimination. For a population of 210 000 MSM about
12 000 individuals with more than 18 sexual partners per
year had to use PrEP to eliminate HIV.
The analysis in Fig. 1a referred to values of the steady-
state prevalence. In practice, reaching elimination, viz the
steady state with zero HIV prevalence and incidence,
required a long time (Fig. 1c and d). At the elimination
threshold (PrEP uptake of 64%), HIV prevalence and
incidence dropped by half 40 and 15 years after initiation
of the PrEP intervention, respectively. After 80 years,
HIV prevalence was still 2.5% and HIV incidence was
reduced by 75%. Given a time frame, the higher PrEP
uptake was the larger impact it had on HIV prevalence.
Higher PrEP uptakes would be necessary given a shorter
time frame to achieve a certain reduction in HIV
prevalence (refer to Supplementary Fig. 3, http://
links.lww.com/QAD/B377).
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(a) (b)
(c) (d)
Fig. 1. Impact of preexposure prophylaxis uptake in the highest risk group. (a) Steady-state HIV prevalence (bars, the left y-axis)
and effective reproduction number Re (dots, the right y-axis), (b) preexposure prophylaxis coverage in the highest risk group, (c and
d) time-dependent dynamics of HIV prevalence and incidence for increasing levels of preexposure prophylaxis uptake and
baseline antiretroviral treatment. Preexposure prophylaxis uptake (bar color) denoted the percentage of highest-riskMSM initiating
preexposure prophylaxis within 1 year. Preexposure prophylaxis coverage was computed as the steady-state percentage of HIV-
negative MSMwho were on preexposure prophylaxis in the highest risk group. The black line in part (a) is Re¼1. Below this value
of Re HIV prevalence became zero indicating HIV elimination. The elimination occurred when preexposure prophylaxis uptake
exceeded 64%.We compared the above scenario with the scenario in
which PrEP was targeted to individuals in the two highest
risk groups (Fig. 2). The total number of individuals on
PrEP was the same in both scenarios, ranging from about
1200 to 12 000 MSM for the range of PrEP uptakes used
in Figs. 1 and 2. As expected, in the second scenario the
same number of PrEP users was achieved at lower PrEP
uptake because PrEP was distributed among individuals
in the two highest risk groups instead of the highest risk
individuals only (compare Figs. 1 and 2 by bar color). In
this scenario, steady-state HIV prevalence could be
reduced by PrEP from 8 to 4.6% and Re from 3 to 1.8
(Fig. 2a). As compared with the first scenario in which
our model predicted HIV elimination (Fig. 1a), in the
second scenario the elimination by PrEP was not feasible
in the full range of explored parameters.
Significantly, we came to the same conclusion of
impossibility of elimination in a scenario with increasingART uptake levels and no PrEP (Fig. 3). If ART uptake
increased from baseline 30 to 99.9%, prevalence decreased
from 8 to 2% and Re decreased from 3 to 1.3 (Fig. 3a). For
this range of uptakes the model predicted an increase in
ART coverage from baseline 80 till 99% (Fig. 3b) but still
no elimination.
As ART coverage has been increasing in the Netherlands,
we further extended our analysis of the first scenario with
PrEP uptake in the highest risk group assuming that ART
uptake levels increased as well (Fig. 4). As expected, the
impact of both interventions was higher than the impact
of PrEP alone in the sense that higher ART uptake
required lower PrEP uptake to achieve the same
reduction in the steady-state HIV prevalence (compare
Figs. 1 and 4 by PrEP uptake level). If ART uptake
increased from baseline 30 to 40 and 50%, elimination
could be achieved at PrEP uptake of 50 and 40%,
respectively (Fig. 4a). In terms of intervention coverage
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(a) (b)
Fig. 2. Impact of preexposure prophylaxis uptake in two groups with highest risk. (a) Steady-state HIV prevalence (bars, the left y-
axis) and effective reproduction number Re (dots, the right y-axis), (b) preexposure prophylaxis coverage in the next to highest and
in the highest risk groups for increasing levels of preexposure prophylaxis uptake and baseline antiretroviral treatment.
Preexposure prophylaxis uptake (bar color) was equal in both groups and the total number of preexposure prophylaxis users
in the two groups was the same as the number of preexposure prophylaxis users in the highest risk group in Fig. 1. Figures 1 and 2
can be compared by bar color. Preexposure prophylaxis coverage was computed per risk group as the steady-state percentage of
HIV-negative MSM who were on preexposure prophylaxis in that group. The values of Re were always far above 1 (black line in
part b) indicating that elimination by preexposure prophylaxis was not feasible.(Fig. 4b and c), HIV was eliminated at ART coverage of
85% and PrEP coverage of 76%. If ART coverage
increased to 89%, then PrEP coverage had to be 70%
for elimination.
The predictions of our model were so far based on the
assumption of 86% PrEP effectiveness and an average
duration of taking PrEP of 5 years. In Fig. 5, we relaxed
these assumptions for the first scenario, changing one of
these parameters and keeping the other parameter fixed at
its default value. When we increased effectiveness to 95%,
Re became less than 1 at 50% PrEP uptake (76% PrEP
coverage). If effectiveness decreased to 75%, the
elimination threshold was at 92% PrEP uptake (92%
coverage). For lower uptakes, PrEP led to a significant(a) (
Fig. 3. Impact of antiretroviral treatment uptake if preexposure pro
the left y-axis) and effective reproduction number Re (dots, the right
for increasing levels of antiretroviral treatment uptake. Antiretrovira
initiating antiretroviral treatment within 1 year. Antiretroviral treatm
HIV-infected population on antiretroviral treatment. The black line i
HIV by antiretroviral treatment was not feasible in this scenario.reduction in the steady-state prevalence. Shorter use of
PrEP (Fig. 5c and d) made elimination prospects even less
favorable. If MSM stayed on PrEP for 2.5 years, annual
PrEP uptake had to be at least 86% to get to zero steady-
state prevalence. For the duration of 1 year, PrEP uptake
had to exceed 99.5% for this to happen. The PrEP
coverage for HIV elimination with PrEP duration of 2.5
and 1 years was 82 and 84%, respectively.Discussion
The use of PrEP among MSM in the Netherlands was
found to be an effective intervention for reducing HIVb)
phylaxis is unavailable. (a) Steady-state HIV prevalence (bars,
y-axis), (b) antiretroviral treatment coverage in the population
l treatment uptake (bar color) denoted the percentage of MSM
ent coverage was computed as the steady-state percentage of
n part (a) is Re¼1. As Re never decreased below 1, eliminating
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(c)
Fig. 4. Impact of increasing antiretroviral treatment levels in the entire population and preexposure prophylaxis uptake in the
highest risk group. (a) Steady-state HIV prevalence (bars, the left y-axis) and effective reproduction number Re (dots, the right y-
axis), (b) antiretroviral treatment coverage in the population and (c) preexposure prophylaxis coverage in the highest risk group for
increasing levels of preexposure prophylaxis uptake (bar color). At 40 and 50% antiretroviral treatment uptake themodel predicted
HIV elimination (Re¼1 – black line) at 50 and 40% preexposure prophylaxis uptake (bar color), respectively. In terms of coverage,
HIV was eliminated at 85% antiretroviral treatment coverage and 76% preexposure prophylaxis coverage, or at 89% antiretroviral
treatment coverage and 70% preexposure prophylaxis coverage.prevalence and eventually driving HIV to elimination.
The precise amount of expected reduction depended,
however, on how PrEP was distributed in the
population. PrEP uptake by the highest risk individuals
was the most promising intervention with HIV
elimination achieved at PrEP coverage of 82% (about
5.7% of all MSM or 12 000 with more than 18 new
partners per year). The time it took to reach
elimination after the introduction of PrEP was rather
long. For PrEP coverage at the elimination threshold,
HIV prevalence and incidence decreased by half within
40 and 15 years, and it took more than 80 years for
them to drop to zero.
If the number of PrEP users was the same as in the initial
scenario but they were distributed among the two highest
risk groups then the impact of PrEP on prevalence was
much less. For the range of explored parameters, the
maximum prevalence reduction (from 8 to 4.6%) for
PrEP use in two groups was observed when PrEP
coverage among the next to highest and highest riskindividuals reached 46%. Although there were signifi-
cantly more PrEP users in the next to highest risk group
they had lower numbers of partners and thus contributed
less to transmission. This suggests that PrEP should be
primarily targeted at the highest risk individuals, and a
large PrEP effect on the population level HIV prevalence
cannot be achieved by an extensive PrEP use in
individuals with lower risk.
Given that ART coverage among MSM in the
Netherlands has been increasing for years [2,24], we
extended our model predictions for the scenario with
PrEP uptake by the highest risk group and increasing
ART uptake levels. If ART coverage increased by 9%
from the current levels, the elimination was feasible at
PrEP coverage of about 70%. On the other hand, our
model predicted that increasing treatment uptake alone
would be insufficient to reach elimination. These results
agree with those of [14,25,26] who showed that a
significant reduction in HIV transmission could not be
achieved without PrEP.
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Fig. 5. Impact of preexposure prophylaxis effectiveness and duration of taking preexposure prophylaxis in the highest risk group.
(a and c) Steady-state HIV prevalence (bars, the left y-axis) and effective reproduction number Re (dots, the right y-axis), (b and d)
preexposure prophylaxis coverage in the highest risk group for increasing levels of preexposure prophylaxis uptake (bar color). In
parts (a and b), two sets of bars corresponded to preexposure prophylaxis effectiveness of 95 and 75%, whereas preexposure
prophylaxis duration was fixed at the default value of 5 years. In parts (c and d), two sets of bars corresponded to preexposure
prophylaxis duration of 1 and 2.5 years, whereas preexposure prophylaxis effectiveness was fixed at the default value of 86%.PrEP can be administered daily or on demand (before and
after a sexual contact) [3], with both regimens
demonstrating an effectiveness of 86% [5,6] that we used
in our analysis. Our choice of modeling daily PrEP only
was motivated by the interim findings on the preference
of PrEP regimes in the AMPrEP project, which showed
that 72% of participants chose to start daily PrEP [3,27].
We also obtained predictions of the model for other values
of effectiveness and varying duration of using PrEP to
reflect a real world setting where individuals are
themselves responsible for obtaining and taking PrEP
drugs. As expected, HIV elimination prospects were less
favorable for lower effectiveness and shorter duration on
PrEP but the reduction in steady-state prevalence was
still significant.
The strength of our approach is that it can be used to
investigate the feasibility of HIV elimination and to
determine the levels of PrEP and ART coverage necessary
to achieve it. Moreover, the model is very general and
could be applied for MSM populations in other Western
countries such as the United Kingdom, Switzerland or
the USA.Our model had several simplifying assumptions that are
likely to affect the inferences made in this study. We
calibrated ART uptake using the estimate of ART
coverage in the population of MSM as a whole. For this
reason, we assumed ART uptake independent of risk
level. In practice, higher risk individuals could test for
HIV more frequently and start ART sooner upon HIV
diagnosis [28]. In case of heterogeneous ART uptake in
the future we expect that HIV elimination would be
easier to achieve because the effective reproduction
number is lower than in the case of homogeneous ART
uptake [19].
Our model did not take some details of partnership
dynamics into account that could influence the impact of
PrEP on HIV prevalence. We assumed that taking PrEP
will not affect the contribution of concurrent partner-
ships in the population, so concurrencyeffects are present
before and after implementation of intervention strate-
gies. In a situation with serosorting, PrEP use would be
more effective, if only used in serodiscordant partner-
ships. We also expect that if mixing would be changed
from intermediate to proportionate (assortative), HIV
2622 AIDS 2018, Vol 32 No 17would be more (less) evenly distributed among risk
groups [19], and providing HIV to high-risk individuals
would be less (more) effective.
The model also assumed that risk behavior of individuals
did not change with time. Changes in risk behavior can
have a very important effect on HIV transmission. For
example, short-term increases in risk behavior known as
episodic risk were shown to greatly affect the prospects of
HIV elimination by test-and-treat [29]. The effect of
changing risk groups may be the replenishment of the
high-risk group with susceptible individuals, which leads
to an increase in transmission, and the diffusion of HIV
infection into low-risk groups by HIV-infected men
moving to lower risk levels. In reality, use of PrEP should
be targeted as much as possible to persons and time
periods, in which increased risk of HIV acquisition
occurs, for example at persons with high rate of partner
change and low condom use. PrEP will be more effective
if it is taken before the onset of such a period, so in that
sense our analysis can be viewed as providing a minimal
estimate for impact of PrEP on HIV prevalence.
Finally, we did not consider a possible increase in risk
behavior induced by PrEP initiation. These behavioral
changes known as risk compensation were observed in
Dutch MSM after ART became widely available in
1996 [30–33] and could occur upon PrEP implemen-
tation as well. A recent study based on a stochastic
network-based mathematical model of HIV transmis-
sion among MSM in the United States concluded that
risk compensation is unlikely to decrease the preventive
impact of PrEP [34].
In conclusion, our analysis suggests that PrEP for HIV
prevention among MSM could, in principle, eliminate
HIV from this population in the Netherlands. To achieve
elimination, public health services should target PrEP to
individuals with highest risk behavior. The current level
of PrEP uptake by the Dutch MSM may reduce HIV
transmission but is insufficient to make a significant
impact on the epidemic.Acknowledgements
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